Literature DB >> 33543454

Homing Peptides for Cancer Therapy.

Prakash Lingasamy1, Tambet Teesalu2,3,4.   

Abstract

Tumor-homing peptides are widely used for improving tumor selectivity of anticancer drugs and imaging agents. The goal is to increase tumor uptake and reduce accumulation at nontarget sites. Here, we describe current approaches for tumor-homing peptide identification and validation, and provide comprehensive overview of classes of tumor-homing peptides undergoing preclinical and clinical development. We focus on unique mechanistic features and applications of a recently discovered class of tumor-homing peptides, tumor-penetrating C-end Rule (CendR) peptides, that can be used for tissue penetrative targeting of extravascular tumor tissue. Finally, we discuss unanswered questions and future directions in the field of development of peptide-guided smart drugs and imaging agents.

Entities:  

Keywords:  Affinity chromatography; Angiogenic integrins; C-end Rule; Extracellular matrix; In vivo peptide phage display; Multistep targeting; Nanomedicine; Nanoparticle; Neuropilin-1; T7 phage; Tumor-homing peptide; Tumor-penetrating peptide; gC1qR/p32

Mesh:

Substances:

Year:  2021        PMID: 33543454     DOI: 10.1007/978-3-030-58174-9_2

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  186 in total

1.  Targeted delivery of doxorubicin through conjugation with EGF receptor-binding peptide overcomes drug resistance in human colon cancer cells.

Authors:  Shibin Ai; Tao Jia; Weilun Ai; Jianli Duan; Yongmei Liu; Jing Chen; Xin Liu; Fan Yang; Yuan Tian; Zebo Huang
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

2.  Proapoptotic peptide-mediated cancer therapy targeted to cell surface p32.

Authors:  Lilach Agemy; Venkata R Kotamraju; Dinorah Friedmann-Morvinski; Shweta Sharma; Kazuki N Sugahara; Erkki Ruoslahti
Journal:  Mol Ther       Date:  2013-08-20       Impact factor: 11.454

Review 3.  Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes.

Authors:  Meghdad Abdollahpour-Alitappeh; Majid Lotfinia; Tohid Gharibi; Jalal Mardaneh; Behrouz Farhadihosseinabadi; Pegah Larki; Babak Faghfourian; Koushan Sineh Sepehr; Kazem Abbaszadeh-Goudarzi; Ghasem Abbaszadeh-Goudarzi; Behrooz Johari; Mohammad Reza Zali; Nader Bagheri
Journal:  J Cell Physiol       Date:  2018-11-27       Impact factor: 6.384

4.  Nanoparticle-induced vascular blockade in human prostate cancer.

Authors:  Lilach Agemy; Kazuki N Sugahara; Venkata Ramana Kotamraju; Kunal Gujraty; Olivier M Girard; Yuko Kono; Robert F Mattrey; Ji-Ho Park; Michael J Sailor; Ana I Jimenez; Carlos Cativiela; David Zanuy; Francisco J Sayago; Carlos Aleman; Ruth Nussinov; Erkki Ruoslahti
Journal:  Blood       Date:  2010-06-29       Impact factor: 22.113

5.  Phage treatment of human infections.

Authors:  Stephen T Abedon; Sarah J Kuhl; Bob G Blasdel; Elizabeth Martin Kutter
Journal:  Bacteriophage       Date:  2011-03

6.  Biological evaluation of a novel doxorubicin-peptide conjugate for targeted delivery to EGF receptor-overexpressing tumor cells.

Authors:  Shibin Ai; Jianli Duan; Xin Liu; Stephanie Bock; Yuan Tian; Zebo Huang
Journal:  Mol Pharm       Date:  2011-02-02       Impact factor: 4.939

7.  De novo design of a tumor-penetrating peptide.

Authors:  Luca Alberici; Lise Roth; Kazuki N Sugahara; Lilach Agemy; Venkata R Kotamraju; Tambet Teesalu; Claudio Bordignon; Catia Traversari; Gian-Paolo Rizzardi; Erkki Ruoslahti
Journal:  Cancer Res       Date:  2012-11-14       Impact factor: 12.701

8.  Destabilization of the epidermal growth factor receptor (EGFR) by a peptide that inhibits EGFR binding to heat shock protein 90 and receptor dimerization.

Authors:  Aarif Ahsan; Dipankar Ray; Susmita G Ramanand; Ashok Hegde; Christopher Whitehead; Alnawaz Rehemtulla; Yoshihiro Morishima; William B Pratt; Yoichi Osawa; Theodore S Lawrence; Mukesh K Nyati
Journal:  J Biol Chem       Date:  2013-07-29       Impact factor: 5.157

Review 9.  Targeted cancer therapy through antibody fragments-decorated nanomedicines.

Authors:  Abbas Alibakhshi; Fatemeh Abarghooi Kahaki; Shahrzad Ahangarzadeh; Hajar Yaghoobi; Fatemeh Yarian; Roghaye Arezumand; Javad Ranjbari; Ahad Mokhtarzadeh; Miguel de la Guardia
Journal:  J Control Release       Date:  2017-11-05       Impact factor: 9.776

10.  Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp.

Authors:  Khalid O Alfarouk; Christian-Martin Stock; Sophie Taylor; Megan Walsh; Abdel Khalig Muddathir; Daniel Verduzco; Adil H H Bashir; Osama Y Mohammed; Gamal O Elhassan; Salvador Harguindey; Stephan J Reshkin; Muntaser E Ibrahim; Cyril Rauch
Journal:  Cancer Cell Int       Date:  2015-07-15       Impact factor: 5.722

View more
  5 in total

Review 1.  Nanoparticles as Physically- and Biochemically-Tuned Drug Formulations for Cancers Therapy.

Authors:  Valentina Foglizzo; Serena Marchiò
Journal:  Cancers (Basel)       Date:  2022-05-17       Impact factor: 6.575

Review 2.  The role of cell-penetrating peptides in potential anti-cancer therapy.

Authors:  Meiling Zhou; Xi Zou; Kexin Cheng; Suye Zhong; Yangzhou Su; Tao Wu; Yongguang Tao; Li Cong; Bin Yan; Yiqun Jiang
Journal:  Clin Transl Med       Date:  2022-05

Review 3.  Peptide-Based Nanoparticles for Therapeutic Nucleic Acid Delivery.

Authors:  Prisca Boisguérin; Karidia Konate; Emilie Josse; Eric Vivès; Sébastien Deshayes
Journal:  Biomedicines       Date:  2021-05-20

4.  SCMTHP: A New Approach for Identifying and Characterizing of Tumor-Homing Peptides Using Estimated Propensity Scores of Amino Acids.

Authors:  Phasit Charoenkwan; Wararat Chiangjong; Chanin Nantasenamat; Mohammad Ali Moni; Pietro Lio'; Balachandran Manavalan; Watshara Shoombuatong
Journal:  Pharmaceutics       Date:  2022-01-04       Impact factor: 6.321

5.  Homing Peptide-Based Targeting of Tenascin-C and Fibronectin in Endometriosis.

Authors:  Lorena Simón-Gracia; Kristina Kiisholts; Vilma Petrikaitė; Allan Tobi; Merli Saare; Prakash Lingasamy; Maire Peters; Andres Salumets; Tambet Teesalu
Journal:  Nanomaterials (Basel)       Date:  2021-11-30       Impact factor: 5.076

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.